MindWalk (NASDAQ:HYFT) Upgraded at Zacks Research

MindWalk (NASDAQ:HYFT) was upgraded by stock analysts at Zacks Research from a “strong sell” rating to a “hold” rating in a research note issued on Monday, Zacks reports.

A number of other research analysts have also commented on the company. Wall Street Zen upgraded MindWalk from a “sell” rating to a “hold” rating in a research report on Saturday, August 15th. HC Wainwright restated a “buy” rating on shares of MindWalk in a research report on Monday, July 20th. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of MindWalk in a research note on Wednesday, July 15th. One investment analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $5.00.

MindWalk Trading Up 0.7%

Shares of NASDAQ HYFT opened at $1.48 on Monday. MindWalk has a 1-year low of $0.99 and a 1-year high of $2.99. The company has a 50-day moving average of $1.36 and a two-hundred day moving average of $1.37. The company has a market cap of $69.13 million, a PE ratio of -5.69 and a beta of 0.82. The company has a current ratio of 1.84, a quick ratio of 1.75 and a debt-to-equity ratio of 0.43.

MindWalk (NASDAQ:HYFT) last issued its quarterly earnings results on Monday, September 14th. The company reported ($0.09) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.04). MindWalk had a negative net margin of 105.11% and a negative return on equity of 133.26%. The company had revenue of $2.73 million during the quarter, compared to analyst estimates of $3.25 million. As a group, equities analysts expect that MindWalk will post -0.21 earnings per share for the current fiscal year.

Hedge Funds Weigh In On MindWalk

A hedge fund recently bought a new position in MindWalk stock. BlackRock Inc. purchased a new stake in MindWalk Holdings Corp. (NASDAQ:HYFT) in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 154,411 shares of the company’s stock, valued at approximately $244,000. BlackRock Inc. owned about 0.33% of MindWalk at the end of the most recent reporting period. Institutional investors own 6.70% of the company’s stock.

MindWalk Company Profile

ImmunoPrecise Antibodies Ltd., together with its subsidiaries, engages in antibody production and related services in the United States, Canada, Europe, and internationally. The company offers a range of antibodies, enzymes, enzyme activity assays, arthritis animal products, proteins, deiminated proteins, organoid growth factors, and hybridoma products for research purposes. Its services include custom antigen modeling, design, and manufacturing; B cell sorting, screening, and sequencing; custom, immune, and naive phage display production and screening; transgenic animals and multi-species antibody discovery; bi-specific, tri-specific, VHH, and VNAR (shark) antibody manufacturing; DNA cloning, protein and antibody downstream processing; antibody characterization on label-free biosensors and antibody engineering; transient and stable cell line generation; antibody optimization and humanization; hybridoma production with multiplexed, high-throughput screening, and clone-picking; and cryopreservation.